US 11,667,662 B2
Modulators of 5′-nucleotidase, ecto and the use thereof
Laurent Pierre Paul Debien, San Francisco, CA (US); Juan Carlos Jaen, Burlingame, CA (US); Jaroslaw Kalisiak, Mountain View, CA (US); Kenneth V. Lawson, San Francisco, CA (US); Manmohan Reddy Leleti, Dublin, CA (US); Erick Allen Lindsey, San Diego, CA (US); Dillon Harding Miles, Berkeley, CA (US); Eric Newcomb, Menlo Park, CA (US); Jay Patrick Powers, Pacifica, CA (US); Brandon Reid Rosen, San Mateo, CA (US); and Ehesan Ui Sharif, Menlo Park, CA (US)
Assigned to ARCUS BIOSCIENCES, INC., Hayward, CA (US)
Filed by ARCUS BIOSCIENCES, INC., Hayward, CA (US)
Filed on Mar. 19, 2021, as Appl. No. 17/206,896.
Application 17/206,896 is a continuation of application No. 17/009,590, filed on Sep. 1, 2020, granted, now 11,001,603.
Application 17/009,590 is a continuation of application No. 16/273,843, filed on Feb. 12, 2019, granted, now 10,981,944.
Application 16/273,843 is a continuation of application No. 15/400,748, filed on Jan. 6, 2017, granted, now 10,239,912, issued on Mar. 26, 2019.
Claims priority of provisional application 62/324,077, filed on Apr. 18, 2016.
Claims priority of provisional application 62/276,564, filed on Jan. 8, 2016.
Prior Publication US 2021/0371449 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 19/23 (2006.01); A61K 31/7076 (2006.01); C07H 19/16 (2006.01); C07H 19/20 (2006.01); C07H 19/207 (2006.01); C07F 9/6561 (2006.01); C07H 19/04 (2006.01); A61K 31/706 (2006.01); A61K 45/06 (2006.01); A61K 31/7052 (2006.01); A61K 31/7064 (2006.01); C07H 19/14 (2006.01)
CPC C07H 19/23 (2013.01) [A61K 31/70 (2013.01); A61K 31/706 (2013.01); A61K 31/7052 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C07F 9/6561 (2013.01); C07F 9/65616 (2013.01); C07H 19/04 (2013.01); C07H 19/14 (2013.01); C07H 19/16 (2013.01); C07H 19/20 (2013.01); C07H 19/207 (2013.01)] 9 Claims
 
1. A compound having the structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.